A Lesson About Antibodies and Eyeballs

It's like turning off the sprinklers in your front yard and expecting the fire in your basement to go out.

Immunovant's trials tested 12 weeks of high-dose batoclimab (680 mg weekly) followed by 12 weeks at a lower dose (340 mg weekly). The company noted that proptosis improved more during the aggressive early phase, supporting the idea that deeper antibody suppression helps. But by week 24, neither trial showed a statistically significant difference versus placebo on the primary endpoint: a 2 mm or greater reduction in eye bulging.

Not Just Immunovant's Problem

Argenx, the company that dominates the FcRn space with Vyvgart, also discontinued its own TED studies after they appeared likely to miss their goals. Two companies. Two drugs. Same class. Same disease. Same result.

That pattern matters. It suggests the mechanism itself doesn't translate to orbital autoimmunity, not just that one particular molecule fell short. The approved TED drug, teprotumumab, works by blocking IGF-1R (a completely different target that hits the disease more upstream). FcRn inhibitors, by contrast, act downstream: they clear antibodies faster but don't stop the immune system from making them, and they don't touch the T cells, complement activation, or fibroblast changes that drive the structural damage in TED.

The Strategic Pivot

Immunovant isn't walking away from FcRn entirely. It's walking away from batoclimab specifically, redirecting everything toward IMVT-1402, a second-generation FcRn blocker. The company says it will apply lessons from the batoclimab program to this newer molecule.

The remaining IMVT-1402 pipeline includes Graves' disease, myasthenia gravis, CIDP (a nerve disorder), difficult-to-treat rheumatoid arthritis, Sjögren's disease, and cutaneous lupus. Data from two of those programs—difficult-to-treat rheumatoid arthritis and cutaneous lupus erythematosus—is expected in the second half of 2026.

Notably, the stock didn't crater. Shares actually rose approximately 24% after the company's broader update, with Leerink analysts saying the IMVT-1402 data "meet or exceed expectations." Wall Street seems to believe the next-gen molecule can succeed where batoclimab couldn't.

What This Means for the FcRn Class

The broader lesson is sobering for anyone who thought FcRn inhibitors would be the Swiss Army knife of autoimmunity. The class clearly works in myasthenia gravis. It has traction in immune thrombocytopenia and CIDP (efgartigimod is approved for both in Japan). But the TED failures, combined with a Phase 2 miss for rozanolixizumab in CIDP, show that deep IgG lowering doesn't automatically equal clinical benefit.

The competitive landscape is narrowing accordingly:

• Argenx is playing the broadest game: neurology, hematology, dermatology, and rheumatology across multiple indications.
• UCB is concentrating rozanolixizumab on neurologic autoimmunity.
• J&J is differentiating nipocalimab in maternal-fetal diseases (like hemolytic disease of the newborn) where it has Breakthrough Therapy designation.

Each company is retreating to the indications where the biology is most clearly IgG-driven and the clinical signal is strongest.

The Bottom Line

Immunovant learned something the field probably should have suspected: you can't fix a compartmentalized, multifactorial eye disease just by vacuuming antibodies out of the bloodstream. The FcRn class remains powerful, but its boundaries are becoming clearer. And for investors, the message is straightforward: not every autoimmune disease is an FcRn disease, no matter how elegant the mechanism looks on a slide deck.

Denmark's $861M Bet to Become Europe's Biotech Capital

The Novo Nordisk Foundation just made its largest donation ever: $861 million over a decade to turn Denmark's BioInnovation Institute into a European biotech powerhouse. The catch? It's not just about drugs anymore.